EXOZ EXOZYMES INC.
Price Chart
Executive Summary
EXOZ is conducting a dilutive underwritten public offering of common stock and warrants under its existing $50M shelf registration. All key terms (share count, price, proceeds) are placeholder amounts, but the offering structure is confirmed: units of 2 shares + 1 warrant, with warrants exercisable at 125% of the offering price for 2 years. The underwriter MDB Capital is also the company's largest shareholder (47.79%), creating a FINRA Rule 5121 conflict of interest. The filing explicitly discloses substantial doubt about going concern and warns of immediate and substantial dilution for new investors.
Actionable Insight
The dilutive offering, combined with a going-concern warning and a conflicted underwriter that is also the largest shareholder, signals severe capital needs. Monitor the final pricing and share count in the subsequent 424B5 filing — the actual dilution magnitude will determine the near-term stock impact. The 12-month company lock-up and 6-month insider lock-up provide some near-term supply relief post-offering.
Key Facts
- Dilutive offering of common stock and warrants under $50M shelf registration (S-3 filed Jan 2026)
- Units consist of 2 shares + 1 warrant; warrant exercise price set at 125% of offering price, 2-year term
- Underwriter MDB Capital is the largest shareholder (47.79%) and has board representation — FINRA conflict of interest declared
- Company discloses substantial doubt about ability to continue as a going concern in the risk factors
- Public float is ~$15.2M (based on 4.6M affiliate-held shares and $11.70 reference price), limiting primary offering size under S-3 I.B.6 to ~$5M
- 8,478,992 shares outstanding pre-offering; offering size and resulting dilution are undisclosed (placeholder amounts)
- 12-month company lock-up and 6-month insider lock-up from closing
- Proceeds intended for NCT business development, R&D, and working capital
Financial Impact
Offering size and pricing are undisclosed (placeholder amounts). Based on public float of ~$15.2M and S-3 I.B.6 limitation, the primary offering is capped at roughly $5M. Underwriting discount is 7% plus up to $100K expenses and $175K QIU fee. Immediate and substantial dilution is explicitly warned.
Risk Factors
- Immediate and substantial dilution to existing shareholders
- Going-concern risk — company may not survive without this capital raise
- Conflicted underwriter (MDB Capital owns 47.79% and controls board seats) raises governance concerns
- Warrant overhang (2-year term, exercisable at 125% of offering price) could pressure stock
- No trading market for warrants; liquidity risk for warrant holders
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-025698 |
| Document: 0001493152-26-025698-index-headers.html | 0001493152-26-025698 |
| Document: 0001493152-26-025698-index.html | 0001493152-26-025698 |
| Document: 0001493152-26-025698.txt | 0001493152-26-025698 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
8-K
| $9.00 awaiting T+1 | awaiting T+1 | — | $8.62 (+4.22%) |
|
Jun 8, 2026
1d ago
|
424B5
| $9.02 awaiting T+1 | awaiting T+1 | — | $8.62 (+4.43%) |
|
Jun 4, 2026
5d ago
|
424B5
| $9.35 $9.34 | ▲ +0.11% | ▼ −2.49% | $8.62 (+7.81%) |
|
May 29, 2026
11d ago
|
424B5
| $9.85 $9.67 | ▲ +1.78% | ▲ +2.04% | $8.62 (+12.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access